Patient Advocacy: Lessons Learned from Top Pharma Companies About Relationships with Patient Advocacy Groups

As patient advocacy groups exert greater influence on key treatment and policy decisions, biopharmaceutical companies are intensifying their efforts to create and maintain relationships with these groups. At the same time, organizations need to be compliant with the regulatory policies and guidelines.

Best Practices, LLC undertook this benchmarking research to identify effective practices in patient advocacy group collaboration and relationship management. This study examines the key lessons learned by top pharma companies in partnering with patient advocacy to shape policies, improve access, and boost patient voice. The research includes a chapter with qualitative data from respondents regarding lessons learned and success stories.

KEY TOPICS

• Understanding the “advocacy” landscape
• Advocacy lessons learned
• Success stories

• Mapping the advocacy landscape to succeed: Assess the landscape of advocacy and community- interest groups to understand the broad spectrum of players, special interests and possible collaborators. Align objectives with different advocacy groups based on a particular therapeutic area or region. Be transparent while sharing information that can be deemed useful for advocacy groups. Aim for building long-term relationships.

Best Practices, LLC engaged 74 leaders supporting patient advocacy at 61 biopharmaceutical companies through a benchmarking survey. More than 60% of participants are at the director/ senior director level. Nearly 65% of participants are from the United States.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.